Principal Investigator Matthias Meier
Bioengineering and Microfluidics
Oliver Bruns' research is dedicated to the development of excellent techniques for biomedical imaging. The advancement of new targeted contrast agents and novel imaging modalities will pave the way for personalized therapy and high precision treatments in the near future. Imaging in the short-wave infrared region (SWIR) is a new technology for biomedical applications. It provides several advantages over the visible and near-infrared regions: general lack of autofluorescence, low light absorption by blood and tissue, and reduced scattering. In this wavelength range tissues become translucent. Recent progress in detection technology and the development of probes demonstrated that, in principal, SWIR imaging enables applications which were previously not feasible with any other technique. These advantages will enable new capabilities in preclinical imaging. Most SWIR imaging setups so far are used for proof of principal demonstrations only.
Human fat tissue has evolved to serve as a major energy reserve. An imbalance between energy intake and expenditure leads to an expansion of adipose tissue and degeneration of the endocrine function of the pancreas. Maintenance of this energy imbalance over longer times leads to obesity and metabolic disorders such as type 2 diabetes, for which clinical cures are not yet available.
Our research project aims to develop and use pancreatic and adipose tissue models outside organisms in sizes of micrometers for studying the differentiation of human inducible pluripotent stem cells (hiPSCs) into functional tissue. For assembly of so called organoids, we combine microfluidic chip technologies with quantitative bioanalytics. In particular, the integration of organoids on microfluidic chip platforms is exploited in our lab to dynamically control their chemical, cell architectural, and mechanical microenvironment of hiPSCs. With novel single cell resolution in situ detection systems, we aim to reveal, which microenvironmental stem cell niche factors are required to differentiate hiPSCs into metabolic responsive cells, communication pathways between organs, and the importance of cell heterogeneity in organs for their proper function.
Dr. Matthias Meier
Principal Investigator, Bioengineering and Microfluidics
Matthias Meier is a German biophysicist who received his PhD from the University of Basel in Switzerland in 2006. In 2008 he was awarded with the Feodor-Lynen postdoctoral fellowship from the Alexander von Humboldt Foundation and worked 4 years with Steven Quake at Stanford University. With help of an Emmy-Noether-Fellowship from the German Research Foundation he returned to Europe and established an independent research group at the Microsystem Engineering department of the University of Freiburg. In 2017 Dr. Meier received the ERC Consolidator grant for performing research in medical engineering field of Organ-on-Chips. In 2018 Matthias Meier joined the Helmholtz Pioneer Campus.
Dr. Matthias Meier
Positions and Career
2018 - present
Principal Investigator at Helmholtz Pioneer Campus, Helmholtz Zentrum München, Germany
2012 - 2018
Independent Research Group Leader (DFG Emmy-Noether Fellow) at IMTEK, University of Freiburg, Germany
2009 - 2011
Postdoc at Stanford University, Laboratory of Professor Stephen Quake, USA
2008 - 2009
Postdoc at University of Chicago, Laboratory of Professor Rustem Ismagilov, USA
1998 – 2004
Biochemistry, University of Regensburg, Germany
2003 - 2004
Diploma in Biophysics, University of Regensburg, Germany
Supervisor: Prof. Dr. Eike Brunner
2004 - 2008
PhD in Biophysics / University of Basel, Szitzerland
Supervisor: Prof. Dr. Joachim Seelig
Honors and Awards
Institute de Gennes, Synergy Microfluidics & Biology, Paris, France
MicroTas, South Korea (1 PhD student talk)
W2 Professorship application, Westfälische-Wilhelms-Universität, Münster, Germany
MicroTas, San Antonio, USA (2 Talks from my PhD students)
DFG (German Research Foundation), Biophysical Meeting, Germany
ISMB Meeting, Boston, USA
DKFZ, Synthetic Biology Meeting, Heidelberg, Germany
W2 Professorship application (2nd ranked), Düsseldorf, Germany
MicroTas, Freiburg (1 PhD student talk), Germany
Dachema, Synthetic Biology Conference, Germany
02/2010 & 07/2011
Gordon Conference, Biological Microfluidics, Italy
EMBL, Group Leader application (2nd ranked), Germany
2014 - present
Member of the German Biophysical Society
2014 - present
Technical Board Member of MicroTas
Current Third Party Funding
2018 - 2023
European Research Council (ERC) - Consolidator
Consolidator Grant “MicroAdiPS Chip: Micro Fat Tissue on Chip
Research focus: Organ-on-Chip
Karakus U, Thamamongood T, Ciminski K, Ran W, Günther SC, Pohl MO, Eletto D, Jeney C, Hoffmann D, Reiche S, Schinköthe J, Ulrich R, Wiener J, Hayes MGB, Chang MW, Hunziker A, Yángüez E, Aydillo T, Krammer F, Oderbolz J, Meier M, Oxenius A, Halenius A, Zimmer G, Benner C, Hale BG, García-Sastre A, Beer M, Schwemmle M, Stertz S.
Nature. 2019 Mar;567(7746):109-112. doi: 10.1038/s41586-019-0955-3.
Schneider N, Gäbelein C, Wiener J, Georgiev T, Gobet N, Weber W, Meier M.
ACS Chem Biol. 2018 Nov 16;13(11):3049-3053. doi: 10.1021/acschembio.8b00594.
Wu X, Schneider N, Platen A, Mitra I, Blazek M, Zengerle R, Schüle R, Meier M.
Proc Natl Acad Sci U S A. 2016 Jul 19;113(29):E4143-50. doi: 10.1073/pnas.1601207113.
Blazek M, Santisteban TS, Zengerle R, Meier M.
Lab Chip. 2015 Feb 7;15(3):726-34. doi: 10.1039/c4lc00797b.
Proximity ligation assay for high-content profiling of cell signaling pathways on a microfluidic chip.
Blazek M, Betz C, Hall MN, Reth M, Zengerle R, Meier M.
Mol Cell Proteomics. 2013 Dec;12(12):3898-907. doi: 10.1074/mcp.M113.032821.
Helmholtz Pioneer Campus
Helmholtz Zentrum München
Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
Ingolstädter Landstr. 1